Archive · 29 Sep 2026
US Sets Zero Tariff on Indian Rare-Disease Drugs
The United States has set the tariff on certain medicines from India at zero percent.
These medicines include rare-disease and specialty drugs.
A tariff is an extra charge placed on imported goods.
Indian drug companies send many medicines to the United States.
Most of those shipments are generic medicines.
Generics are not affected by the new tariff for now.
However, that exemption may not last permanently.
The Commerce Secretary is expected to review the issue within a year.
The United States has set a 0% tariff on rare-disease and specialty drugs from India.
The US is a major market for Indian pharmaceutical exports.
Generic medicines account for most Indian pharmaceutical shipments to the US.
Generics are currently exempt from the new tariff.
The Commerce Secretary is expected to review within a year whether generics should also be covered.
- Who
- The United States and Indian pharmaceutical exporters.
- What
- The US has set a 0% tariff on rare-disease and specialty drugs from India, while generic medicines are currently exempt.
- When
- The new tariff arrangement is in effect; an exact date is not stated. A review of generics is expected within a year.
- Where
- Trade between India and the United States.
- Why
- The measure affects Indian pharmaceutical exports to the US, a major market for those products.
- Tariff rate
- 0% for rare-disease and specialty drugs from India
- Affected trade
- Indian pharmaceutical exports to the United States
- Major market
- The United States is a major market for Indian pharmaceutical exports
- Largest shipment category
- Generic medicines make up most Indian pharmaceutical shipments to the US
- Current generic-drug status
- Generics are exempt from the new tariff for now
- Review timeline
- The Commerce Secretary is expected to review the exemption within a year
- Exemption status
- The generic-drug exemption is not necessarily permanent